A
Annette Baumhauer
Researcher at Bayer
Publications - 10
Citations - 2949
Annette Baumhauer is an academic researcher from Bayer. The author has contributed to research in topics: Regorafenib & Hepatocellular carcinoma. The author has an hindex of 7, co-authored 10 publications receiving 2148 citations.
Papers
More filters
Journal ArticleDOI
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix,Shukui Qin,Philippe Merle,Alessandro Granito,Yi Hsiang Huang,György Bodoky,Marc Pracht,Osamu Yokosuka,Olivier Rosmorduc,Valeriy Breder,René Gerolami,Gianluca Masi,Paul Ross,Tianqiang Song,Jean-Pierre Bronowicki,Isabelle Ollivier-Hourmand,Masatoshi Kudo,Ann-Lii Cheng,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Richard S. Finn,Marie Aude Leberre,Annette Baumhauer,Gerold Meinhardt,Guohong Han +25 more
TL;DR: Regorafenib is the only systemic treatment shown to provide survival benefit in HCC patients progressing on sorafenIB treatment, and future trials should explore combinations of regorAFenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate the sequence of sorafanib and regorafinib.
Journal ArticleDOI
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
Richard S. Finn,Philippe Merle,Alessandro Granito,Yi Hsiang Huang,György Bodoky,Marc Pracht,Osamu Yokosuka,Olivier Rosmorduc,René Gerolami,Chiara Caparello,Roniel Cabrera,Charissa Chang,Weijing Sun,Marie Aude Leberre,Annette Baumhauer,Gerold Meinhardt,Jordi Bruix +16 more
TL;DR: Examination of characteristics and outcomes of patients with hepatocellular carcinoma who were treated with regorafenib after they had disease progression during sorafenIB treatment show that regoracenib conferred a clinical benefit regardless of the last sorafanib dose or TTP on prior sorafinib.
Journal ArticleDOI
Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.
Jordi Bruix,Philippe Merle,Alessandro Granito,Yi Hsiang Huang,György Bodoky,Osamu Yokosuka,Olivier Rosmorduc,Valeriy Breder,René Gerolami,Gianluca Masi,Paul Ross,Shukui Qin,Tianqiang Song,Jean-Pierre Bronowicki,Isabelle Ollivier-Hourmand,Masatoshi Kudo,Lei Xu,Annette Baumhauer,Gerold Meinhardt,Guohong Han +19 more
TL;DR: This data indicates that skin toxicity is a known adverse effect of multikinase inhibitors that was shown to be a predictor of OS in patients with HCC treated with sorafenib and this data supports the use of this drug for HCC patients.
Journal ArticleDOI
LBA-03Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial
Jordi Bruix,Philippe Merle,Alessandro Granito,Y.-H. Huang,György Bodoky,Osamu Yokosuka,Olivier Rosmorduc,Valeriy Breder,René Gerolami,Gianluca Masi,J. Ross Paul,Shukui Qin,Tianqiang Song,Jean-Pierre Bronowicki,Isabelle Ollivier-Hourmand,Masatoshi Kudo,MA LeBerre,Annette Baumhauer,Gerold Meinhardt,Guohong Han +19 more
Journal ArticleDOI
Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial.
Richard S. Finn,Philippe Merle,Alessandro Granito,Yi Hsiang Huang,György Bodoky,Marc Pracht,Osamu Yokosuka,Olivier Rosmorduc,René Gerolami,Chiara Caparello,Roniel Cabrera,Charissa Chang,Weijing Sun,Guohong Han,Marie-Aude Le Berre,Annette Baumhauer,Gerold Meinhardt,Jordi Bruix +17 more
TL;DR: Outcomes for the sequence of SOR followed by REG are described, which showed that REG improves overall survival (OS) in patients who progressed during SOR treatment (HR 0.63, 95% CI 0.50, 0.79; P < 0.001).